BPC-157
Also known as Body Protection Compound 157, PL 14736, Bepecin
BPC-157 is a synthetic 15-residue peptide studied across models of tendon, muscle, and gut-lining repair. A research-use profile: sequence, class, research contexts, and how it's handled.
BPC-157 is one of the most-referenced peptides in the soft-tissue and gastrointestinal research literature — which is precisely why it draws so much confusion. Almost everything written about it online skips the two facts that actually define it: it is a short, fully synthetic sequence, and the body of work around it is experimental, not clinical.
This page keeps to what is verifiable — its composition, the systems it has been studied in the context of, and how a laboratory handles it — and stays out of the territory of outcomes and dosing, which are neither settled nor appropriate to claim.
A stable synthetic fragment corresponding to a partial sequence of a protein originally isolated from gastric juice. It carries no disulfide bonds and is notable in the literature for its stability in aqueous solution.
What it is, structurally
BPC-157 is a chain of fifteen amino acids. Its sequence corresponds to a partial region of a larger protein first characterized in gastric juice; the isolated fragment is produced synthetically rather than extracted. There are no cysteine residues and therefore no disulfide bridges, which is part of why the sequence is often described as unusually robust for a peptide of its size.
The proline-rich stretch near the N-terminus (three consecutive prolines) is a distinctive structural feature and a useful way to recognize the sequence when comparing certificates of analysis.
The research contexts it appears in
In the published literature, BPC-157 shows up most often in models of connective-tissue and gut-lining repair — tendon and ligament work, muscle and other soft tissue, and the gastrointestinal mucosa. These are the research areas it is associated with; they describe where scientists have studied it, not effects promised to anyone.
It is frequently discussed alongside TB-500 (a thymosin β4 fragment) because the two are studied in overlapping recovery contexts, though they are structurally unrelated.
Reading a BPC-157 certificate of analysis
Because the sequence is short and well defined, a mass-spectrometry trace on a certificate of analysis should line up cleanly with a 15-residue peptide, and an HPLC trace should show a dominant single peak. A lot that reports a purity figure but no method, or no batch identifier, is telling you less than it appears to. Every lot we list is tied to its own certificate — verify yours by its batch number.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized. Stored sealed and cold; in research settings it is reconstituted with bacteriostatic water only when a protocol requires it, then kept refrigerated. Handle per accepted laboratory practice.
Verify a certificate by lot →Common questions
It is produced synthetically. Its sequence corresponds to a partial region of a protein originally characterized in gastric juice, but the research compound is manufactured, not extracted.
Fifteen amino acids (a pentadecapeptide), with a characteristic run of three prolines near the start of the chain.
Both are studied in overlapping soft-tissue recovery research contexts, so the literature and discussion frequently pair them — even though they are structurally different molecules.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.